Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry
Event:
ESC Congress 2023
Topic:
Antiarrhythmic Drug Treatment
Session:
Remodelling, prognosis, and outcomes in atrial fibrillation
Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program
Event:
ESC Congress 2021 - The Digital Experience
Topic:
Anticoagulants
Session:
Pharmacology and pharmacotherapy e-posters
Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF
Event:
EHRA 2021
Topic:
Oral Anticoagulation
Session:
Prevention of stroke in atrial fibrillation